Why Did the Placebo Benchmark Change the Estimated Psilocybin Effect?

A network meta-analysis can compare treatments studied in different trials, but its estimates depend on how the trials are connected. Hsu and colleagues examined whether using a different placebo benchmark changed the estimated effect of psilocybin on depressive symptoms.

Why distinguish the placebo groups?

The researchers pooled randomized trials involving adults with depressive symptoms and used change on the 17-item Hamilton Depression Rating Scale as the primary outcome. They distinguished placebo responses in psychedelic trials from those in escitalopram trials. Placebo response was lower in the psychedelic-trial group. The authors considered unsuccessful blinding a possible contributor because noticeable effects may influence participants’ expectations about which treatment they received.

What changed in the model?

The standardized mean difference for high-dose psilocybin was 0.88 when the model used the placebo benchmark from psychedelic trials and 0.31 when it used the benchmark from antidepressant trials. These are comparative estimates from the analysis. The change illustrates how much the estimated effect depended on the reference group.

What the comparison supports

Differences across trial populations and settings matter for comparisons assembled through a network. The alternate benchmark is a sensitivity analysis of those differences. It does not identify how much of the observed difference came from participants guessing their assignment.

Source

Hsu TW, Tsai CK, Kao YC, et al. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ. 2024;386:e078607. DOI 10.1136/bmj-2023-078607.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Which Assumptions Drove a Psilocybin Cost-Effectiveness Model?

A decision model can show which assumptions most affect estimated costs. McCrone and colleagues used such a model to compare psilocybin-assisted therapy with medication, cognitive behavioral therapy, and their combination for severe depression. What the model projected The model simulated response, remission, and relapse over six months using inputs from…

Spread the love

Read Article: Which Assumptions Drove a Psilocybin Cost-Effectiveness Model?

Can a Meta-Analysis Identify the Best Psychological Support Protocol for Psilocybin Trials?

Psilocybin-assisted therapy trials can combine the drug with different forms of psychological support. Chen and colleagues asked whether the support protocol was associated with differences in depressive symptoms across studies. What the review compared The analysis included 10 eligible studies with 515 adults. The authors classified the protocols by whether…

Spread the love

Read Article: Can a Meta-Analysis Identify the Best Psychological Support Protocol for Psilocybin Trials?

Why Did the Placebo Benchmark Change the Estimated Psilocybin Effect?

A network meta-analysis can compare treatments studied in different trials, but its estimates depend on how the trials are connected. Hsu and colleagues examined whether using a different placebo benchmark changed the estimated effect of psilocybin on depressive symptoms. Why distinguish the placebo groups? The researchers pooled randomized trials involving…

Spread the love

Read Article: Why Did the Placebo Benchmark Change the Estimated Psilocybin Effect?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us